Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $24 from $20 and keeps a Neutral rating on the shares following the Q1 report. The firm also added an “upside 90-day short-term view” on the shares. Tandem will attend the ADA meeting on June 20-22 and generally, stocks trade up into such events, even if it doesn’t “hold” the price appreciation afterwards as positioning normalizes, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care Gains CE Mark Approval
- Tandem Diabetes Care: Promising Growth Driven by Robust Pipeline and Strategic Initiatives
- Positive Outlook for Tandem Diabetes Care with Strong Recovery and Growth Opportunities
- Tandem Diabetes Care Reports Record Sales and Strategic Growth
- Tandem Diabetes price target lowered to $24 from $33 at Baird